Ryan Cohlhepp
Known title: President, COO & Interim CEOCIK: 0002034665
Associated companies
Transaction History
| BCAX | ▲ Buy | Option Exercise | 17,500 | $66K | 9/8/2026 | View on chart |
| BCAX | ▼ Sell | Open Market | 14,058 | $320K | 9/8/2026 | View on chart |
| BCAX | ▼ Sell | Open Market | 3,442 | $81K | 9/8/2026 | View on chart |
| BCAX | ▲ Buy | Option Exercise | 18,750 | $71K | 8/10/2026 | View on chart |
| BCAX | ▼ Sell | Open Market | 18,750 | $525K | 8/10/2026 | View on chart |
| BCAX | ▼ Sell | Open Market | 536 | $16K | 7/9/2026 | View on chart |
| BCAX | ▲ Buy | Option Exercise | 18,750 | $71K | 7/8/2026 | View on chart |
| BCAX | ▼ Sell | Open Market | 22,833 | $657K | 7/8/2026 | View on chart |
| BCAX | ▼ Sell | Open Market | 4,306 | $128K | 7/8/2026 | View on chart |
| BCAX | ▼ Sell | Open Market | 1,075 | $33K | 7/8/2026 | View on chart |
| BCAX | ▲ Buy | Option Exercise | 8,000 | $30K | 5/15/2026 | View on chart |
| BCAX | ▼ Sell | Open Market | 8,000 | $162K | 5/15/2026 | View on chart |
| BCAX | ▼ Sell | Open Market | 4,500 | $91K | 5/15/2026 | View on chart |
| BCAX | ▲ Buy | Option Exercise | 8,000 | $30K | 4/15/2026 | View on chart |
| BCAX | ▼ Sell | Open Market | 8,000 | $184K | 4/15/2026 | View on chart |
| BCAX | ▼ Sell | Open Market | 4,500 | $104K | 4/15/2026 | View on chart |
| BCAX | ▼ Sell | Open Market | 8,000 | $157K | 3/16/2026 | View on chart |
| BCAX | ▼ Sell | Open Market | 4,500 | $88K | 3/16/2026 | View on chart |
| BCAX | ▲ Buy | Option Exercise | 8,000 | $30K | 3/16/2026 | View on chart |
| BCAX | ▲ Buy | Option Exercise | 12,892 | $49K | 3/3/2026 | View on chart |
| BCAX | ▼ Sell | Open Market | 12,892 | $234K | 3/3/2026 | View on chart |
| BCAX | ▼ Sell | Open Market | 4,500 | $82K | 3/3/2026 | View on chart |
| BCAX | ▲ Buy | Option Exercise | 3,108 | $12K | 2/25/2026 | View on chart |
| BCAX | ▼ Sell | Open Market | 3,108 | $56K | 2/25/2026 | View on chart |
| BCAX | ▼ Sell | Open Market | 523 | $9K | 2/25/2026 | View on chart |
| BCAX | ▼ Sell | Open Market | 3,828 | $69K | 1/22/2026 | View on chart |
| BCAX | ▼ Sell | Open Market | 149 | $3K | 1/15/2026 | View on chart |
| BCAX | ▲ Buy | Option Exercise | 25,000 | $111K | 12/26/2025 | View on chart |
| BCAX | ▲ Buy | Option Exercise | 8,000 | $30K | 12/15/2025 | View on chart |
| BCAX | ▼ Sell | Open Market | 8,000 | $149K | 12/15/2025 | View on chart |
| BCAX | ▼ Sell | Open Market | 4,500 | $84K | 12/15/2025 | View on chart |
| BCAX | ▲ Buy | Option Exercise | 8,000 | $30K | 11/21/2025 | View on chart |
| BCAX | ▼ Sell | Open Market | 8,000 | $144K | 11/21/2025 | View on chart |
| BCAX | ▼ Sell | Open Market | 4,500 | $81K | 11/21/2025 | View on chart |
| BCAX | ▲ Buy | Option Exercise | 8,000 | $30K | 10/15/2025 | View on chart |
| BCAX | ▼ Sell | Open Market | 8,000 | $145K | 10/15/2025 | View on chart |
| BCAX | ▼ Sell | Open Market | 4,500 | $82K | 10/15/2025 | View on chart |
| BCAX | ▲ Buy | Option Exercise | 8,000 | $30K | 10/7/2025 | View on chart |
| BCAX | ▼ Sell | Open Market | 8,000 | $144K | 10/7/2025 | View on chart |
| BCAX | ▼ Sell | Open Market | 2,900 | $52K | 10/7/2025 | View on chart |
| BCAX | ▲ Buy | Option Exercise | 24,000 | $91K | 10/6/2025 | View on chart |
| BCAX | ▼ Sell | Open Market | 24,000 | $433K | 10/6/2025 | View on chart |
| BCAX | ▼ Sell | Open Market | 15,600 | $282K | 10/6/2025 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 13, 2026
BCAX flagged as potentially overvalued on book value
A recent analysis suggests Bicara Therapeutics stock may be overvalued when compared to its book value. This valuation concern is notable given that the stock is currently trading near its 52-week low and has an RSI of 30.1, indicating it is in oversold territory. While the average analyst target is $35.50, the wide range of estimates reflects significant uncertainty about the company's future performance.
BCAX flagged as potentially overvalued on book value. A recent analysis suggests Bicara Therapeutics stock may be overvalued when compared to its book value. This valuation concern is notable given that the stock is currently trading near its 52-week low and has an RSI of 30.1, indicating it is in oversold territory. While the average analyst target is $35.50, the wide range of estimates reflects significant uncertainty about the company's future performance.